newsfilter
← Latest News
Business Wire·

bioAffinity Technologies Reports Accelerating Month-Over-Month Growth in CyPath® Lung Test Volume

  • bioAffinity Technologies announced that CyPath® Lung test volume in October was 111% higher than the 2025 year-to-date monthly average.
  • Tests processed since the start of 2025 have more than doubled, with consistent month-over-month growth reported through the first 10 months.
  • Third-quarter sales volume increased by 95% compared to the prior quarter.
  • Medical practices with multiple CyPath® Lung orders rose 106% in the third quarter versus the prior quarter 67% in October versus the 2025 year-to-date monthly average.
  • CyPath® Lung utilizes advanced flow cytometry AI, fluorescent porphyrin, 92% sensitivity, 87% specificity, 88% accuracy in detecting lung cancer in high-risk patients with nodules under 20mm.
  • The test is marketed as a Laboratory Developed Test by Precision Pathology Laboratory Services, a subsidiary of bioAffinity Technologies.